**SOPHiA GENETICS**, a leading provider of cloud-native healthcare technology focusing on data-driven medicine, is thrilled to announce the worldwide release of **MSK-IMPACT enhanced by SOPHiA DDM**, presented at the Association for Molecular Pathology (AMP) Annual Meeting. By leveraging this groundbreaking solution, institutions globally can gain from Memorial Sloan Kettering Cancer Center’s (MSK) exceptional comprehensive genomic profiling (CGP) application integrated with the SOPHiA DDM Platform, known for its superior accuracy and efficiency.
“Rolling out MSK-IMPACT, powered by SOPHiA DDM, marks a pivotal advancement in our mission to broaden global access to precision oncology,” stated **Dr. Philippe Menu**, Chief Product Officer and Chief Medical Officer at SOPHiA GENETICS. “Following our previous successful introduction of MSK-ACCESS with SOPHiA DDM, we’re eager to continue enhancing our fruitful collaboration with MSK. This launch strengthens our dedication to making advanced tumour profiling technology accessible more broadly, particularly to underserved populations.”
**Kojo S. J. Elenitoba-Johnson, M.D.**, Pathology Department Chair at MSK, remarked, “Our shared vision with SOPHiA GENETICS is firmly rooted in advancing precision medicine and extending our top-tier testing solutions to patients globally.”
Through **MSK-IMPACT empowered by SOPHiA DDM**, entities achieve heightened precision in oncology analytics, bolstering the detection accuracy of somatic mutations even in genes integral to current pharmaceutical R&D initiatives, like MTAP. The paired tumour-normal analysis enables clinicians and researchers to identify somatic mutations with increased confidence, mitigating the risk of incorrectly classifying germline variants as tumour-specific. Additionally, organizations benefit from the global collective knowledge network of SOPHiA GENETICS, contributing to a dynamic repository of real-world data and insights from diverse cohorts.
**Sofiva Genomics**, a top molecular diagnostics firm in Taiwan, is among the first to embrace this innovation. This partnership began in 2022 when they deployed the SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution.
Chia-Cheng Hung, General Manager at Sofiva Genomics, shared, “Our collaboration with SOPHiA GENETICS has significantly augmented our capabilities in providing region-specific, precise genomic testing. With access to cutting-edge technology, we advance our cancer research endeavors in Taiwan.”
**MSK-IMPACT combined with SOPHiA DDM** streamlines the workflow, taking around five days from DNA extraction to the final report generation. Clinicians and researchers also benefit from **OncoKB**, MSK’s Precision Oncology Knowledge Base, enhancing the interpretative effectiveness through informed, actionable insights powered by SOPHiA DDM analyses. Analytical validation for MSK-IMPACT with SOPHiA DDM indicated a high concordance to the single-site MSK-IMPACT test, achieving: 99.3% positive percent agreement (PPA) for SNV/Indel detection; 94.6% PPA for CNV detection; 99.4% overall percent agreement (OPA) for microsatellite instability (MSI) detection; 98.8% OPA for tumour mutational burden (TMB) detection.
**SOPHiA GENETICS** is committed to transforming health outcomes by expanding access to data-driven medicine across the globe. They developed the SOPHiA DDM Platform, which interprets intricate genomic and multi-source data, delivering real-time results and insights to a wide network of hospitals, laboratories, and biopharmaceutical institutions.